<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892343</url>
  </required_header>
  <id_info>
    <org_study_id>RRK6458</org_study_id>
    <nct_id>NCT03892343</nct_id>
  </id_info>
  <brief_title>Effects of Renal Transplantation on Uraemic Cardiomyopathy</brief_title>
  <acronym>RETRACT</acronym>
  <official_title>A Prospective Study of the Effects of Renal Transplantation on Uraemic Cardiomyopathy Using Magnetic Resonance Imaging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Birmingham NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) is associated with a high risk of death and morbidity due to
      cardiovascular disease. Much of this is caused by left ventricular disease characterised by
      abnormal muscle thickness and scaring. This process appears to start early in the course of
      CKD and causes heart failure and dangerous abnormal heart rhythms. Previous work suggests
      that the process may be reversible by kidney transplantation but almost all of the studies
      are small, retrospective and lack scientific rigour. Furthermore, they almost all use
      echocardiography, which is inaccurate in patients with CKD. The investigators plan to perform
      the first large, prospective, controlled, blind-analysed study using cardiac magnetic
      resonance imaging to determine whether CKD associated cardiomyopathy is reversed by kidney
      transplantation and if so, whether factors such as blood pressure and mediators of metabolic
      bone disease/fibrosis are important in effecting this change. Greater understanding of the
      mechanisms responsible for CKD associated cardiomyopathy could lead to future strategies and
      treatments to improve the high cardiovascular mortality associated with this condition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Mass</measure>
    <time_frame>One year.</time_frame>
    <description>Calculated by Cardiac MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Native Myocardial T1 Times.</measure>
    <time_frame>One year.</time_frame>
    <description>Measured using T1 mapping techniques (MOLLI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>One year.</time_frame>
    <description>24hr Ambulatory Blood pressure monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Analysis.</measure>
    <time_frame>One Year</time_frame>
    <description>To calculate augmentation index as a marker of arterial stiffness.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>Transplant recipients</arm_group_label>
    <description>Patients undergoing live donor kidney transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-transplanted</arm_group_label>
    <description>Patients on the deceased donor waiting list without prospect of a live donor transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.</description>
    <arm_group_label>Non-transplanted</arm_group_label>
    <arm_group_label>Transplant recipients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Markers of CKD-MBD: - calcium, phosphate, alkaline phosphatase and PTH will be analyzed in
      serum by mass spectroscopy and FGF-23 will be analyzed by ELISA at 0 and 12 months.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will comprise of patients with end-stage renal failure currently
        awaiting either live or deceased donor transplantation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients registered on the kidney transplant waiting list at the University Hospital
             Birmingham NHS Foundation Trust.

          2. Ages over 18 years

        Exclusion Criteria

          1. Non-standard anti-rejection treatment, post transplant.

          2. Previous history of being unable to tolerate MRI scanner.

          3. Contraindication to MRI - eg metal fragments in ey
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Ferro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Birmingham NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luke Pickup, MBBS</last_name>
    <phone>07828791429</phone>
    <email>luke.pickup2@uhb.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Ferro, MD</last_name>
    <phone>01213715839</phone>
    <email>Charles.ferro@uhb.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Pickup, MBBS</last_name>
      <phone>07828791429</phone>
      <email>luke.pickup2@uhb.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Charles Ferro, MD</last_name>
      <phone>01213715839</phone>
      <email>Charles.ferro@uhb.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Birmingham NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Charles Ferro, Dr</investigator_full_name>
    <investigator_title>Professor Charles Ferro</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

